Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00285818 · ClinicalTrials.gov registry record · NA
Mifepristone Treatment for Patients With Non-psychotic Major Depressive Disorder Receiving Bilateral ECT
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT00285818: Completed NA study, sponsored by Stanford University.
NCT00285818 is a NA study that has completed, run by Stanford University. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00285818, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to see whether the medication mifepristone is an effective and tolerable treatment for increasing the clinical effectiveness of electroconvulsive therapy (ECT) and protecting cognitive function during ECT. Both Mifepristone and ECT appear to normalize hyperfunctioning of the hypothalmic-pituitary-adrenal (HPA) axis, which has been found among patients with major depression referred for ECT. The combination of these two treatments in major depression may lead to a more rapid clinical response than ECT alone. Additionally, there appears to be a connection between pre-ECT higher cortisol levels due to HPA axis hyperfunctioning and post-ECT cognitive impairment. Administration of mifepristone prior to and during ECT treatment may reduce cortisol levels and reduce the incidence of cognitive impairment observed after ECT.
Interventions
- DRUG Placebo Oral Capsule
- DRUG Mifepristone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2003-01 |
| Est. Completion | 2009-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00285818
The ClinicalTrials.gov registry entry for NCT00285818 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Capsule is the first listed.
NCT00285818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00285818 about?
NCT00285818 is a clinical study titled "Mifepristone Treatment for Patients With Non-psychotic Major Depressive Disorder Receiving Bilateral ECT". The purpose of this study is to see whether the medication mifepristone is an effective and tolerable treatment for increasing the clinical effectiveness of electroconvulsive therapy (ECT) and protecting cognitive function during ECT. Both Mifepristone and ECT appear to normalize hyperfunctioning of...
What is the current status of trial NCT00285818?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2003-01. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00285818?
The interventions under investigation include: Placebo Oral Capsule (DRUG), Mifepristone (DRUG).
Who is sponsoring clinical trial NCT00285818?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.